By addressing these challenges through continued innovation in drug design, delivery technologies, and biomarker-guided patient selection, targeted manipulation of the cGAS-STING pathway offers a compelling avenue to significantly improve outcomes, particularly for patients with aggressive and immunotherapy-resistant breast cancer subtypes like TNBC. The gene discussed is CGAS; the disease is breast carcinoma.